FFA
KROS icon

Farther Finance Advisors’s Keros Therapeutics KROS Stock Holding History

Farther Finance Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.16K Buy
453
+201
+80% +$2.2K ﹤0.01% 4991
2026
Q2 		$2.71K Buy
252
+166
+193% +$1.85K ﹤0.01% 5057
2026
Q1 		$1K Sell
86
-536
-86% -$8.28K ﹤0.01% 5105
2025
Q4 		$12.7K Sell
622
-2,352
-79% -$41.3K ﹤0.01% 3757
2025
Q3 		$47K Buy
+2,974
New +$43.9K ﹤0.01% 2472
2025
Q1 		– Sell
-1
Closed -$16 – 4347
2024
Q4 		$16 Sell
1
-1
-50% -$52 ﹤0.01% 3945
2024
Q3 		$116 Buy
2
+1
+100% +$49 ﹤0.01% 3757
2024
Q2 		$44 Hold
1
– – ﹤0.01% 3706
2024
Q1 		$67 Hold
1
– – ﹤0.01% 3437
2023
Q4 		$40 Buy
+1
New +$31 ﹤0.01% 3405

Other funds holding KROS

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Farther Finance Advisors's KROS Position: Q3 2026 in Review

Farther Finance Advisors increased its Keros Therapeutics (KROS) stake by 80% in Q3 2026, buying an estimated $2.2K and bringing the position to 453 shares worth $5.16K. The position accounts for ﹤0.01% of the portfolio, ranked #4991.

Farther Finance Advisors first reported a position in KROS in Q4 2023 and has held it in 10 quarters since. The position peaked at $47K in Q3 2025. 6 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • Farther Finance Advisors held 453 shares of Keros Therapeutics worth $5.16K as of Q3 2026.
  • Farther Finance Advisors bought 201 Keros Therapeutics shares in Q3 2026, an estimated $2.2K.
  • Keros Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4991 holding.
  • Farther Finance Advisors first reported a position in Keros Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Farther Finance Advisors's Keros Therapeutics position peaked at $47K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.